Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAvMed Aphexda prior auth Coverage Update | OpenPay…
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Aphexda (motixafortide) prior authorization for autologous transplantation in multiple myeloma

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This form governs prior authorization and step-edit requests for Aphexda (motixafortide) when used to mobilize stem cells for autologous transplantation in multiple myeloma patients; it affects prescribers, pharmacists, and AvMed members in North Carolina.

    Policy Summary
    PayerAvMed
    PolicyAphexda (motixafortide) prior authorization for autologous transplantation in multiple myeloma
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization with prescriber signature and supporting documentation including planned transplant date and verification of filgrastim use.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1authorized dosing episodes per transplant
    124 mgmaximum units per dose
    18+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    minimum patient age
    J2277HCPCS code

    Coverage Criteria for Aphexda (motixafortide)

    Initial authorization criteria

    Covered when ALL of the following are met

    Eligibility and prescriber: Member is 18 years of age or older AND prescribed by or in consultation with a hematologist/oncologist
    Indication: Requested medication will be used for autologous transplantation in multiple myeloma patients
    Treatment timing: Planned date of transplantation must be provided

    Prescriber must provide planned transplant date

    Concurrent therapy: Requested medication will be used in combination with filgrastim (G-CSF) (verified by chart notes and/or pharmacy/medical paid claims)
    Administration schedule: Medication, filgrastim, and apheresis will be administered once as a single dose 10 to 14 hours prior to the first apheresis; a second dose (1.25 mg/kg) may be administered 10 to 14 hours prior to a third apheresis (must submit recent chart notes/progress notes detailing planned treatment regimen)
    Dosing limits: One treatment of up to two doses per transplant with maximum 124 mg (2 vials) per dose

    Coverage may NOT be renewed.

    Requests to initiate therapy using samples do not meet preauthorization criteria; use of samples to initiate therapy does not meet step edit/preauthorization criteria and previous therapies will be verified through pharmacy paid claims or submitted chart notes.

    Coding and Billing

    Covered HCPCS CodesHCPCSCovered
    J2277motixafortide (Aphexda) (Medical)
    Diagnosis codes (placeholders)ICD-10
    ICD-10ICD code — space provided for applicable diagnosis code
    inv-06: Maximum units per dose
    Maximum units per dose124 mg (2 vials) per dose
    Maximum doses per treatment episodeUp to two doses per treatment (one treatment per transplant)
    Vial strength referenced62 mg single-dose vial (2 vials = 124 mg)
    inv-07: Vials per dose limit
    Vials per dose limit2 vials per dose
    Applicable vial strength62 mg single-dose vial
    Dose occasions

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization required for Aphexda (J2277)

    Prior authorization is required for Aphexda (motixafortide) (J2277) per this medical prior authorization/step-edit request form; prescriber signature and submitted supporting documentation are required for review.

    • Drug Requested: Aphexda (motixafortide) (J2277) (Medical) is subject to prior authorization as indicated on the form.
    • Prescribing physician must sign and clearly print name on the request; preprinted stamps are not valid.
    Step Therapy

    Samples not acceptable; prior therapy will be verified

    Requests that rely on samples to initiate therapy do not meet step-edit/preauthorization criteria; prior therapies will be verified through pharmacy paid claims or submitted chart notes.

    • Use of samples to initiate therapy is explicitly not acceptable to satisfy the step-edit/preauthorization.
    • Previous therapies will be checked via pharmacy paid claims or chart notes to confirm prior treatment history.

    Background

    Motixafortide (Aphexda) is requested as a stem cell mobilization agent to be used in combination with filgrastim (G-CSF) for autologous transplantation in multiple myeloma patients. Authorization is for one treatment consisting of up to two doses per transplant, with administration of the medication and filgrastim 10 to 14 hours prior to apheresis; a second dose (1.25 mg/kg) may be given 10 to 14 hours prior to a third apheresis. Dosing limits include a maximum of 124 mg (2 vials) per dose and a quantity limit of 2 vials per dose for up to two doses.

    Definitions and Administration Details

    inv-13: Authorized treatment episode
    Authorized treatment episodeOne treatment consisting of up to two doses per transplant
    ReauthorizationCoverage may NOT be renewed
    Age requirementMember must be 18 years of age or older
    inv-14: Administration timing
    Concomitant therapyUse in combination with filgrastim (G-CSF) (verified by chart notes and/or pharmacy/medical paid claims)
    Administration timingAdminister motixafortide 10 to 14 hours prior to apheresis as attested by prescriber
    Second dose timing

    Line of Therapy / Salvage

    salvage

    Use relative to transplantation: Use for autologous transplantation stem cell mobilization; one treatment per transplant with up to two doses

    Covered Regimens and Dosing

    RegimenAdministration timingDose detailsDosing limits
    Aphexda (motixafortide) for stem cell mobilization in autologous transplantation (used with filgrastim [G-CSF])
    Single dose administered 10 to 14 hours prior to the first apheresis; an optional second dose may be administered 10 to 14 hours prior to a third apheresis
    First dose as single dose; second (optional) dose specified at 1.25 mg/kg (prescriber must submit recent chart/progress notes detailing planned regimen)
    One treatment per transplant consisting of up to two doses; maximum 124 mg (2 vials) per dose; quantity limit 62 mg single‑dose vial — 2 vials per dose for two doses only
    Policy Summary
    PayerAvMed
    PolicyAphexda (motixafortide) prior authorization for autologous transplantation in multiple myeloma
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization with prescriber signature and supporting documentation including planned transplant date and verification of filgrastim use.
    SourceLink
    On This Page
    Coverage Criteria for Aphexda (motixafortide)Coding and BillingProvider Actions and RequirementsBackgroundDefinitions and Administration DetailsLine of Therapy / SalvageCovered Regimens and Dosing
    Limit applies for up to two doses per treatment episode
    Documentation Required

    Required prescriber signature and supporting documentation

    The prescriber must sign and clearly print their name on the request (preprinted stamps are not valid) and provide documentation to support each checked clinical criterion including lab results, diagnostics, and chart/progress notes; planned transplant date and verification of filgrastim use must be included.

    • Prescribing physician signature and printed name required on the form.
    • Provide documentation for each checked criterion: lab results, diagnostics, chart/progress notes, planned transplantation date, and evidence of filgrastim (G-CSF) use (chart notes and/or pharmacy/medical paid claims).
    Denial Risk

    Incomplete or illegible submissions may delay or cause denial

    Incomplete, incorrect, or illegible information — including missing documentation, labs, diagnostics, or chart notes — may delay review or result in denial of authorization.

    • Ensure all requested fields (including phone and fax numbers) are complete and legible to avoid delays.
    • Missing supporting documentation for checked clinical criteria may lead to denial.
    If used, second dose (1.25 mg/kg) may be given 10 to 14 hours prior to a third apheresis